Abstract:Heterogeneity of neurodegenerative diseases, including Alzheimer’s disease (AD), has hampered precision diagnosis and prognosis. Machine learning methods are able to dissect neuroanatomical heterogeneity and enable identification of disease subtypes via their imaging signatures. We apply a novel semi‐supervised deep‐learning clustering method to derive dimensions of neurodegeneration, and investigate longitudinal paths in this dimensional system. Analyses used structural MRIs (from the Alzheimer’s Disease Neuroimaging Initiative and the Baltimore Longitudinal Study of Aging; total 2,832 participants; 8,146 scans) including controls and patients with Mild Cognitive Impairment (MCI) and AD. Smile‐GAN identified 4 neurodegenerative patterns/axes (Figure 1): P1, normal anatomy; P2, mild/diffuse atrophy; P3, focal medial temporal atrophy; P4, advanced neurodegeneration. Further application to longitudinal data revealed two distinct progression pathways: P1→P2→P4 and P1→P3→P4. Clinically, P2 participants showed worse performance in executive function than P3 participants (median ADNI‐EF= ‐0.29 vs. ‐0.1, with p=0.038) but had better memory (ADNI‐MEM= ‐0.13 vs. ‐0.39, with p=0.003) (Figure 2). Progression to P4 occurred more rapidly from P3 than P2, with median survival time to progression of 4.5 years and 3.2 years for P2 and P3 MCI/Dementia participants, respectively. Baseline expression of these patterns predicted the pathway and rate of future neurodegeneration, with high accuracy for determining whether P1 participants would progress and whether they would progress to P2 or P3 (Cox‐proportional‐hazard model average concordance index (CI) on the validation set of 0.8±0.02). Pattern expression offered better performance (CI=0.72±0.02) in predicting clinical conversion from MCI to Dementia compared to amyloid/tau (CI=0.69±0.02), with all three together showing modest improvement over pattern performance (CI=0.76±0.02). A composite risk score comprised of pattern probabilities, Abeta, pTau, presence of APOE E4, and ADAS‐cog score was able to predict survival time with an average concordance index, 0.78±0.02 on randomly split validation sets. (Figure 3). Four reproducible volumetric patterns, and 2 major longitudinal pathways were revealed using deep learning, which can be determined on an individual patient basis and has implications for rate of future decline. These pattern‐based biomarkers can enrich the N‐dimension of the A/T/N framework which may inform on clinical trial enrollment and monitoring outcomes in a more personalized manner.

Revealing clinical heterogeneity in a large brain bank cohort

Identification of clinical disease trajectories in neurodegenerative disorders with natural language processing

Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology

Two Distinct Trajectories of Clinical and Neurodegeneration Events in Parkinson’s Disease

Neuroimaging-based variability in subtyping biomarkers for psychiatric heterogeneity

Distinct Longitudinal Clinical-Neuroanatomical Trajectories in Parkinson's Disease Clinical Subtypes: Insight Towards Precision Medicine

Individualized gray matter morphological abnormalities uncover two robust transdiagnostic biotypes

Visual deep learning of unprocessed neuroimaging characterises dementia subtypes and generalises across non-stereotypic samples

Pathologic subtyping of Alzheimer's disease brain tissue reveals disease heterogeneity

Alzheimer's disease heterogeneity explained by polygenic risk scores derived from brain transcriptomic profiles

Disentangling brain heterogeneity via semi‐supervised deep‐learning and MRI: Application to dimensional representations of Alzheimer’s disease

Single-cell atlas of transcriptomic vulnerability across multiple neurodegenerative and neuropsychiatric diseases

Disentangling brain heterogeneity via semi-supervised deep-learning and MRI: dimensional representations of Alzheimer's Disease

Deep learning-based brain transcriptomic signatures associated with the neuropathological and clinical severity of Alzheimer's disease

Exploring the Genetic Heterogeneity of Alzheimer's Disease: Evidence for Genetic Subtypes

Progressive Trajectories of Schizophrenia Across Symptoms, Genes, and the Brain

Neurophysiological Stratification of Major Depressive Disorder by Distinct Trajectories

Robustly uncovering the heterogeneity of neurodegenerative disease by using data-driven subtyping in neuroimaging: A review

Personalized Single-cell Transcriptomics Reveals Molecular Diversity in Alzheimer's Disease

Neuroimaging biomarkers define neurophysiological subtypes with distinct trajectories in schizophrenia

Single-nucleus transcriptome-wide association study of human brain disorders